Milestone Immunogenicity Data leave Avacta on track to move their first therapeutic Affimer into the clinic by 2019.
04 Apr 2017
Avacta Group - Milestone Immunogenicity Data
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group - Milestone Immunogenicity Data
Avacta Group PLC (AVCT:LON) | 45.5 0.5 2.2% | Mkt Cap: 163.4m
- Published:
04 Apr 2017 -
Author:
Dr. Riccardo Lowi -
Pages:
4
Milestone Immunogenicity Data leave Avacta on track to move their first therapeutic Affimer into the clinic by 2019.